Related Experiment Videos
Repeat radiosurgery for idiopathic trigeminal neuralgia
Bruce E Pollock1, Robert L Foote, Michael J Link
1Department of Neurological Surgery, Mayo Clinic College of Medicine, Rochester, MN 55905, USA. pollock.bruce@mayo.edu
International Journal of Radiation Oncology, Biology, Physics
|January 5, 2005
Summary
Repeat radiosurgery for trigeminal neuralgia (TN) offers better pain relief than initial treatment. However, a high rate of facial numbness suggests dose reduction is needed to improve safety.
Area of Science:
- Neurosurgery
- Radiation Oncology
- Pain Management
Background:
- Trigeminal neuralgia (TN) is a debilitating facial pain condition.
- Radiosurgery is a common treatment for TN, but repeat procedures are sometimes necessary.
- The efficacy and safety of repeat TN radiosurgery require further investigation.
Purpose of the Study:
- To evaluate the outcomes of repeat radiosurgery for trigeminal neuralgia.
- To assess the safety profile, including adverse events, of repeat TN radiosurgery.
- To determine optimal dosing strategies for repeat radiosurgery to balance efficacy and morbidity.
Main Methods:
- A retrospective study of 19 patients undergoing repeat trigeminal neuralgia radiosurgery between 1997 and 2002.
- Median follow-up of 24 months, with outcomes categorized as excellent, good, fair, or poor.
- Analysis of pain relief, medication reduction, and incidence of new or worsening facial sensory deficits.
Main Results:
- Excellent pain relief was achieved in 74% of patients after repeat radiosurgery.
- Long-term excellent outcomes were observed in 71% at 1 year and 61% at 2 years.
- Facial numbness or other sensory disturbances occurred in 58% of patients, with 11% developing corneal numbness.
Conclusions:
- Repeat trigeminal neuralgia radiosurgery demonstrates favorable pain control compared to primary treatment.
- The relatively high incidence of bothersome facial numbness necessitates a review of current dosing.
- Dose reduction in repeat radiosurgery is recommended to mitigate treatment-related morbidity while maintaining efficacy.